Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma

Laboratory Investigation

Volumn 91, Issue 2, 2011, Pages 262-272

  Yoneda, Norihide ^a   Sato, Yasunori ^a   Kitao, Azusa ^a   Ikeda, Hiroko ^b   Sawada Kitamura, Seiko ^b   Miyakoshi, Masami ^a   Harada, Kenichi ^a   Sasaki, Motoko ^a   Matsui, Osamu ^a   Nakanuma, Yasuni ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

CK19 positive HCC; EGF; EGFR; histogenesis; prognosis

Indexed keywords

ALPHA FETOPROTEIN; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 10; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ARTICLE; CELL PROLIFERATION; DISEASE FREE SURVIVAL; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALPHA-FETOPROTEINS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 8; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79551576947     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.161     Document Type: Article

References (36)

1. Parkin D. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
3. Tang Z, Ye S, Liu Y, et al. A decades studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187-196.
4. Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007;141:196-202.
5. Van Eyken P, Sciot R, Paterson A, et al. Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988;19:562-568.
6. Robrechts C, De Vos R, Van den Heuvel M, et al. Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver 1998;18:288-293.
7. Yoon D, Jeong J, Park Y, et al. Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med J 1999;40:472-477.
8. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-857.
9. Wu P, Fang J, Lau V, et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996;149:1167-1175.
10. Ding S, Li Y, Tan Y, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81.
11. Yang X, Xu Y, Shi G, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 2008;14:3850-3859.
12. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49:138-151.
13. Moll R, Franke W, Schiller D, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
14. Osborn M, van Lessen G, Weber K, et al. Differential diagnosis of gastrointestinal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. Lab Invest 1986;55:497-504.
15. van Eyken P, Sciot R, van Damme B, et al. Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient. Virchows Arch A Pathol Anat Histopathol 1987;412:63-72.
16. Lai Y, Thung S, Gerber M, et al. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med 1989;113:134-138.
17. Roskams T, De Vos R, Van Eyken P, et al. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol 1998;29:455-463.
18. Limaye P, Bowen W, Orr A, et al. Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology 2008;47:1702-1713.
19. Michalopoulos G, Barua L, Bowen W. Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury. Hepatology 2005;41:535-544.
20. Nishikawa Y, Doi Y, Watanabe H, et al. Transdifferentiation of mature rat hepatocytes into bile duct-like cells in vitro. Am J Pathol 2005;166: 1077-1088
21. Michalopoulos G, Bowen W, Mulé K, et al. Hepatocytes undergo phenotypic transformation to biliary epithelium in organoid cultures. Hepatology 2002;36:278-283.
22. Michalopoulos G, Bowen W, Mulé K, et al. Histological organization in hepatocyte organoid cultures. Am J Pathol 2001;159:1877-1887.
23. Del Castillo G, Alvarez-Barrientos A, Carmona-Cuenca I, et al. Isolation and characterization of a putative liver progenitor population after treatment of fetal pat hepatocytes with TGF-beta. J Cell Physiol 2008;215:846-855.
24. Yoshida M, Nishikawa Y, Omori Y, et al. Involvement of signaling of VEGF and TGF-beta in differentiation of sinusoidal endothelial cells during culture of fetal rat liver cells. Cell Tissue Res 2007;329: 273-282.
25. Xu C, Rosler E, Jiang J, et al. Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. Stem Cells 2005;23:315-323.
26. Zaret K. Hepatocyte differentiation: from the endoderm and beyond. Curr Opin Genet Dev 2001;11:568-574.
27. Heppner G. Tumor heterogeneity. Cancer Res 1984;44:2259-2265.
28. Vermeulen L, Sprick M, Kemper K, et al. Cancer stem cells-old concepts, new insights. Cell Death Differ 2008;15:947-958.
29. Bioulac-Sage P, Balabaud C, Wanless I. Diagnosis of focal nodular hyperplasia: not so easy. Am J Surg Pathol 2001;25:1322-1325.
30. Zhang F, Chen X, Zhang W, et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 2008;52:224-232.
31. Aishima S, Nishihara Y, Kuroda Y, et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol 2007;31:783-791.
32. Buckley A, Burgart L, Sahai V, et al. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008;129:245-251.
33. Tang Z, Qin L, Wang X, et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl) 1998;111:313-318.
34. El-Bassiouni A, Nosseir M, Zoheiry M, et al. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS 2006;114:420-427.
35. Ito Y, Takeda T, Sasaki Y, et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 2001;197:95-100.
36. Villanueva A, Chiang D, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-1983.